Blog

RESEARCH PEPTIDES

Featured Peptides

View All Peptides →

Tesamorelin + Ipamorelin Blend

13mg $120

Add to cart

Retatrutide + Eloralintide Blend

13mg $100

Add to cart

Glutathione

1500mg $50

Add to cart

October 21, 2026

LC526 Lipo-C Fat Blaster: Formulation, Benefits & Protocol

Laboratory Research & Clinical Notice: This article reviews metabolic biochemistry, lipotropic compound pharmacology, and mitochondrial bioenergetics strictly for educational, scientific evaluation, and analytical purposes. References to injectable lipotropic formulations, Lipo-C blends, or specific research protocols do not constitute medical advice or promote unapproved clinical administration. Overcoming stubborn fat loss plateaus requires more than just restricting […]

October 21, 2026

What Is CBL-514? Targeted Fat-Cell Apoptosis & Research

Clinical Research & Educational Notice: This article reviews clinical trial literature, cellular oncology/adipocyte biology, and investigational pharmacology strictly for scientific evaluation and educational reference. References to CBL-514 (frequently searched or referred to in community research as UB514) reflect ongoing clinical trials and do not constitute clinical guidance or endorsement of unapproved self-administration. For decades, body […]

October 21, 2026

Wegovy Pill vs. Orforglipron vs. VK2735: Oral Incretin Comparison

Clinical Research & Educational Notice: This article reviews clinical pharmacology, drug-delivery chemistry, and published trial data strictly for scientific evaluation and educational reference. References to oral semaglutide, orforglipron, and investigational VK2735 tablets reflect peer-reviewed literature and do not constitute clinical prescribing advice. The weekly injectable pen transformed obesity pharmacotherapy, but patient compliance, cold-chain refrigeration requirements, […]

October 21, 2026

Oral VK2735: The Next-Gen Dual GLP-1/GIP Incretin Pill

Clinical Research & Educational Notice: This article reviews clinical pharmacology, oral peptide drug-delivery science, and published Phase 1/2 trial data strictly for scientific evaluation and educational reference. References to investigational compounds such as oral VK2735 reflect ongoing pharmaceutical trials and do not constitute clinical advice or an endorsement of unapproved self-administration. For years, metabolic peptide […]

October 21, 2026

VK2735 Dual Agonist: GLP-1/GIP Mechanisms & Clinical Data

Back to Research & Articles Clinical Research & Educational Notice: This article reviews clinical trial literature, incretin mimetic pharmacology, and preclinical metabolic models strictly for educational, scientific evaluation, and analytical purposes. References to VK2735, dual-receptor agonists, and investigational peptides do not constitute medical advice or encourage self-administration without authorized clinical supervision. The treatment of metabolic […]

October 21, 2026

Which Compounds Cannot Use Regular BAC Water Alone?

You draw your standard volume of bacteriostatic water, angle the needle against the glass, and introduce the liquid into a fresh vial of AOD-9604 or IGF-1 LR3. Instead of melting into a crystal-clear solution, the liquid turns milky white, separates into suspended gelatinous flakes, or leaves a stubborn ring that refuses to dissolve. Your first […]

October 15, 2026

DTI-117: A New Peptide Approach to More Predictable Bowel Care

DTI-117 research explores rapid, on-demand bowel emptying. Understand the new animal findings, potential benefits and planned first human study.

October 15, 2026

Oral Semaglutide Delivery: What Orexo’s New AmorphOX Results Could Mean for Peptide Pills

Orexo’s early AmorphOX results explore another route to oral semaglutide. Learn what absorption means, why formulation matters and what comes next.

October 15, 2026

MOTS-c and Eye Health: New Research Explores Protection Against Diabetic Retinopathy

New MOTS-c research explores retinal blood vessel protection in cells and mice. Discover the findings, potential benefits and next steps for eye health.

October 1, 2026

Icotrokinra ICONIC-TOTAL: Promising Relief for Difficult-to-Treat Psoriasis Sites

Icotrokinra ICONIC-TOTAL explained: study results, benefits, key insights and next steps in clear language, with links to the primary evidence.

Oral Semaglutide OASIS 4: The Trial Behind a New Oral Semaglutide OASIS 4

October 1, 2026

Oral Semaglutide OASIS 4: The Trial Behind a New Weight-Management Tablet

Semaglutide OASIS 4 explained: study results, benefits, key insights and next steps in clear language, with links to the primary evidence.

October 1, 2026

Icotrokinra ANTHEM-UC: A Targeted Oral Peptide Shows Promise in Ulcerative Colitis

Icotrokinra ANTHEM-UC explained: study results, benefits, key insights and next steps in clear language, with links to the primary evidence.

October 1, 2026

Rusfertide VERIFY: A Peptide Approach to Reducing the Phlebotomy Burden

Rusfertide VERIFY explained: study results, benefits, key insights and next steps in clear language, with links to the primary evidence.

Icotrokinra cotrokinra ICONIC-ADVANCE: Why the Direct Oral Psoriasis Comparison Matters

October 1, 2026

Icotrokinra ICONIC-ADVANCE: Why the Direct Oral Psoriasis Comparison Matters

Icotrokinra ICONIC-ADVANCE 1 and 2 explained: study results, benefits, key insights and next steps in clear language, with links to the primary evidence.

October 1, 2026

Icotrokinra ICONIC-LEAD: How an Oral Peptide Reached Clearer-Skin Results

Icotrokinra ICONIC-LEAD explained: study results, benefits, key insights and next steps in clear language, with links to the primary evidence.

October 1, 2026

Semaglutide ESSENCE: A Major Step Forward for MASH and Liver Research

Semaglutide ESSENCE explained: study results, benefits, key insights and next steps in clear language, with links to the primary evidence.

October 1, 2026

Survodutide SYNCHRONIZE-2: New Results Connect Weight Loss and Diabetes Control

Survodutide SYNCHRONIZE-2 explained: study results, benefits, key insights and next steps in clear language, with links to the primary evidence.

October 1, 2026

Survodutide SYNCHRONIZE-1: A Dual-Hormone Peptide Advances in Obesity Research

Survodutide SYNCHRONIZE-1 explained: study results, benefits, key insights and next steps in clear language, with links to the primary evidence.

October 1, 2026

Pemvidutide RECLAIM: A Peptide Trial Points Toward Fewer Heavy-Drinking Days

Pemvidutide RECLAIM explained: study results, benefits, key insights and next steps in clear language, with links to the primary evidence.

October 1, 2026

Pemvidutide IMPACT: What Improving Liver Markers Could Mean for MASH

Pemvidutide IMPACT 48-week update explained: study results, benefits, key insights and next steps in clear language, with links to the primary evidence.

Blog

Featured Peptides

PE-22-28

Tesamorelin + Ipamorelin Blend

Retatrutide + Eloralintide Blend

Cagrilintide

Glutathione

LC526 Lipo-C Fat Blaster: Formulation, Benefits & Protocol

What Is CBL-514? Targeted Fat-Cell Apoptosis & Research

Wegovy Pill vs. Orforglipron vs. VK2735: Oral Incretin Comparison

Oral VK2735: The Next-Gen Dual GLP-1/GIP Incretin Pill

VK2735 Dual Agonist: GLP-1/GIP Mechanisms & Clinical Data

Which Compounds Cannot Use Regular BAC Water Alone?

DTI-117: A New Peptide Approach to More Predictable Bowel Care

Oral Semaglutide Delivery: What Orexo’s New AmorphOX Results Could Mean for Peptide Pills

MOTS-c and Eye Health: New Research Explores Protection Against Diabetic Retinopathy

Icotrokinra ICONIC-TOTAL: Promising Relief for Difficult-to-Treat Psoriasis Sites

Oral Semaglutide OASIS 4: The Trial Behind a New Weight-Management Tablet

Icotrokinra ANTHEM-UC: A Targeted Oral Peptide Shows Promise in Ulcerative Colitis

Rusfertide VERIFY: A Peptide Approach to Reducing the Phlebotomy Burden

Icotrokinra ICONIC-ADVANCE: Why the Direct Oral Psoriasis Comparison Matters

Icotrokinra ICONIC-LEAD: How an Oral Peptide Reached Clearer-Skin Results

Semaglutide ESSENCE: A Major Step Forward for MASH and Liver Research

Survodutide SYNCHRONIZE-2: New Results Connect Weight Loss and Diabetes Control

Survodutide SYNCHRONIZE-1: A Dual-Hormone Peptide Advances in Obesity Research

Pemvidutide RECLAIM: A Peptide Trial Points Toward Fewer Heavy-Drinking Days

Pemvidutide IMPACT: What Improving Liver Markers Could Mean for MASH

Researcher verification